Eris Lifesciences Q1 FY27: Growth Holds, Mix Pressures Margins

Consolidated revenue was 873 crore (up 13% YoY), EBITDA was 296 crore (up 7% YoY) and PAT was 143 crore (up 14.5% YoY).

DBF revenue was 801 crore, growing 14.2% YoY. DBF EBITDA was 278 crore, up 7% YoY, with EBITDA margin at 35%.

DBF gross margin declined to 74% from 77% and EBITDA margin to 35% from 37%, which management attributed largely to product mix shifts toward biologics including insulins and GLP-1.

Management stated the Bhopal facility will be commercialised in Aug-26, with a gradual ramp-up and expectation of being largely on track by the end of Q3 FY27.

Eris highlighted the insulin analogs market as 2,309 crore MAT and growing 9.4% YoY, with Eris currently not present. Management discussed ongoing batch and regulatory work and indicated Aspart could be earlier, while other analogs may come later.

In Jun-26, the presentation stated SUNDAE ranked 1 in prescriptions and units with about 21% Rx share and 20% unit share, and ranked 2 in value with about 14% value share in generic semaglutide.

Swiss Parenterals Q1 FY27 revenue was 72 crore (up 5% YoY) and EBITDA was 18 crore (down 19% YoY). Management said EU CAPA actions are underway and sites are targeted to be audit-ready by Dec-26, with clearer impact expected after Q2 FY27.